Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience
{{output}}
Objective: Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTATATE is increasingly used in the treatment of metastatic neuroendocrine neoplasms (NENs). Marrow toxicity resulting in therapy-related myeloid neoplasms (... ...
